EUCTR2008-001416-20-IT进行中（未招募）不适用
Phase II High Pulse Dose Clinical Trial of Orally Administered ITF 2357 In Patients with Relapsed/Refractory Multiple Myeloma - ND
ITALFARMACO0 个研究点目标入组 22 人开始时间: 2008年5月7日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 22
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Established diagnosis of multiple myeloma according to International Myeloma Working Group diagnostic criteria
- •2.Age ≥ 18 years
- •3.Patient relapsed after at least 2 lines of conventional chemotherapy or high dose therapy with autologous or allogeneic stem cell support, and/or for whom no alternative treatments are available/suitable
- •4.Increasing trend of monoclonal immunoglobulin or Bence-Jones proteinuria through the last 4 consecutive pre-screening measurements, already available in the patient history
- •5.No chemotherapy or other investigational anticancer therapy for at least 3 weeks before the start of the study
- •6.Full recovery from previous toxicities
- •7.ECOG performance status 0-2
- •8.Adequate bone marrow reserve: absolute neutrophil count ≥ 1000/ml; platelet count ≥ 90000/ml
- •9.Adequate liver function: total bilirubin within normal institutional limits (PI center); AST(SGOT)/ALT(SGPT) ≤ 2.5 x institutional upper limit of normal (PI center)
- •10.Adequate renal function: Creatinine ≤ 2.5 mg/dl or creatinine clearance ≥ 50 ml/min
- •11.Either men or women, accepting to practice effective contraception during the entire study period unless documentation of infertility exists. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should immediately inform her treating physician; in this case ITF 2357 treatment will be promptly discontinued
- •12.Able to understand and willing to sign the informed consent form.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Planned autologous or allogeneic bone marrow transplantation within 4 weeks of the initiation of ITF 2357 administration
- •2.Concurrent use of medicines that would confound the interpretation of toxicities and anti-tumour activity of ITF 2357 (i.e. quinolons, macrolides, 5-HT3 antagonists except for palonosetron,)
- •3.Clinically significant illness including, but not limited to, the following: active infection, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, cardiac arrhythmia (present or documented in the past, of any kind), any other condition (including laboratory abnormalities) that in the opinion of the Investigator places the patient to unacceptable risk for adverse outcome if he/she were to participate in the study
- •4.Psychiatric illness/social situations that would limit compliance with study medication and protocol requirements
- •5.Pregnant or lactating women
- •6.Positive blood tests for HIV, HBV, HCV, active EBV and CMV
- •7.Diseases related to active viral infections
- •8.Patients with a marked baseline prolongation of QTc interval (e.g. repeated demonstration of a QTc interval >440 ms for men and >450 ms for women)
- •9.Patients with history of additional risk factors for Torsade de Pointes (e.g. heart failure, family history of Long QT Syndrome).
- •10.The use of concomitant medications with potential risk of Torsade de Pointes and/or that can prolong QTc interval
研究者
相似试验
招募中
2 期
A randomized phase II study of pulsatile high-dose sunitinib versus TAS-102 in patients with metastatic colorectal carcinoma (mCRC).metastatic colorectal carcinoma1001799010017991NL-OMON53126Radboud Universitair Medisch Centrum70
招募中
不适用
A randomized phase II study of pulsatile high-dose sunitinib versus TAS-102 in patients with metastatic colorectal carcinoma (mCRC).NL-OMON27160Radboud UMC60
进行中（未招募）
不适用
A Phase I/II, open-label, dose escalation trial to evaluate the safety, pharmacokinetics, and pharmacodynamics of RAF265 (CHIR-265) administered orally to patients with locally advanced or metastatic melanomalocal advanced or metastatic melanomaMedDRA version: 9.1Level: LLTClassification code 10027481Term: Metastatic melanomaEUCTR2007-005367-10-NLovartis Pharma Services AG211
进行中（未招募）
1 期
A first-in-human trial of safety and efficacy of GEN3017 in subjects with Hodgkin lymphoma or non-Hodgkin lymphomaHodgkin lymphoma or non-Hodgkin lymphomaMedDRA version: 20.0Level: HLGTClassification code: 10025322Term: Lymphomas non-Hodgkin's unspecified histology Class: 10029104MedDRA version: 20.0Level: HLGTClassification code: 10025319Term: Lymphomas Hodgkin's disease Class: 10029104CTIS2023-503348-15-00Genmab A/S240
进行中（未招募）
1 期
A research project for boys with Duchenne muscular dystrophy aged 5-9 years. It aims to find out how safe and well tolerated different doses of the experimental medicine are, when given by mouth after breakfast and evening meal.Duchenne muscular dystrophy (DMD)MedDRA version: 18.1 Level: PT Classification code 10013801 Term: Duchenne muscular dystrophy System Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2015-001967-38-GBSummit (Oxford) Limited24